Набор скоро начнётся NCT07046728

Efficay and Safety of DAROMUN on Patient Treated by Intralesionnal Injection: DAROMEL

— Наблюдательное Injections Intralesional

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: Efficay and Safety of DAROMUN on patient treated by intralesionnal injection: DAROMEL.
Кому может быть актуально: Состояния в реестре: Injections Intralesional. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Франция
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Observationnal Multicentric Study to Evaluate the Safety and the Efficacy of DAROMUN of Melanoma Patient (Resectable Stage IIIB to IIID) Treated by Intralesionnal Injection

Обзор

Melanoma is a malignant tumor originating from melanocytes, with a high metastatic potential, particularly in advanced stages. The standard treatment for resectable melanomas has traditionally been surgery, often followed by adjuvant therapy to reduce the risk of recurrence. However, the emergence of neoadjuvant/perioperative therapies, administered prior to surgery, has revolutionized the management of patients with stage IIIB-C-D melanoma presenting with locoregional macroscopic metastases. Another therapeutic approach involving an intratumoral immunocytokine called DAROMUN (a fusion protein combining an antibody and a cytokine), designed to stimulate antitumor immunity within the melanoma cell microenvironment, was presented at the global oncology congress (ASCO) in June 2024. Preliminary biomarker analyses indicated that treatment with DAROMUN leads to an increase in tumor-infiltrating lymphocytes, particularly CD4+ and CD8+ cells, suggesting immune activation within the tumor microenvironment. This molecule, recently made available through a compassionate use program on the website of the French National Agency for the Safety of Medicines and Health Products (ANSM), may be particularly beneficial for patients who experience recurrence despite prior adjuvant therapy and who have locally advanced, resectable melanoma.The team therefore aim to conduct a real-world, ambispective, multicenter study under the auspices of the Cutaneous Oncology Group (GCC) of the French Society of Dermatology (SFD), focusing on the use of DAROMUN in patients with stage IIIB-IIID locally advanced melanoma.The primary endpoint will be to assess the response rate to treatment according to RECIST 1.1 criteria.Secondary endpoints will include: distant metastasis-free survival, pathological complete response rate, treatment safety profile, and overall survival.

Вмешательства

Другое Efficay and Safety of DAROMUN on patient treated by intralesionnal injection: DAROMEL
Observationnal study with clincal data collection to evaluate the efficiency and the tolerability of DAROMUN

Первичные конечные точки

Objective response rate according to RECIST 1 ( Evaluation Criteria In Solid Tumors ) [Срок оценки: From baseline to 13 months ( september 1, 2024 to october 31, 2025)]

Вторичные конечные точки (2)

Pathological complete response rate (macroscopic) [Срок оценки: From baseline to 13 months ( september 1, 2024 to october 31, 2025)]
Pathological complete response rate (microscopic) [Срок оценки: From baseline to 13 months ( september 1, 2024 to october 31, 2025)]

Критерии участия

Критерии включения

Patient over 18 years old with locally advanced melanoma stage IIIB, IIIC, or IIID.
Patient diagnosed with cutaneous melanoma or melanoma of unknown primary origin.
Disease progression after treatment with immunotherapy in the adjuvant or metastatic setting.
Patient having a contraindication to immunotherapy.
Patient having received at least one intralesional infusion of Daromun.